ENZC (Enzolytics) Net Margin %: -1,473.33% (As of Jun. 2011)


What is Enzolytics Net Margin %?

Enzolytics ENZC -9.09% Net Margin % is -1,473.33% as of Jun. 2011.

Net margin is calculated as Net Income divided by its Revenue. Enzolytics's Net Income for the three months ended in Jun. 2011 was $-0.22 Mil. Enzolytics's Revenue for the three months ended in Jun. 2011 was $0.02 Mil. Therefore, Enzolytics's net margin for the quarter that ended in Jun. 2011 was -1,473.33%.

The historical rank and industry rank for Enzolytics's Net Margin % or its related term are showing as below:


ENZC's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Enzolytics  (OTCPK:ENZC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Enzolytics Net Margin % Related Terms

Enzolytics Net Margin % Historical Data

* Premium members only.

The historical data trend for Enzolytics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Net Margin % Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Net Margin %
0.00 0.00 -6,466.67 -20,308.11

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11,925.00 -4,853.85 -45,066.67 -4,250.00 -1,473.33

Enzolytics Net Margin % Competitor Comparison

For the Biotechnology subindustry, Enzolytics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzolytics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzolytics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Enzolytics's Net Margin % falls into.


Enzolytics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Enzolytics's Net Margin for the fiscal year that ended in Dec. 2010 is calculated as

Net Margin=Net Income (A: Dec. 2010 )/Revenue (A: Dec. 2010 )
=-7.514/0.037
=-20,308.11 %

Enzolytics's Net Margin for the quarter that ended in Jun. 2011 is calculated as

Net Margin=Net Income (Q: Jun. 2011 )/Revenue (Q: Jun. 2011 )
=-0.221/0.015
=-1,473.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,473.33% mean?
Enzolytics (ENZC) has a Net Margin % of -1,473.33% as of Jun. 2011. Net margin is the ratio of total net income to net sales. View historical data on Enzolytics and its competitors.
Is Enzolytics' Net Margin % too high?
Enzolytics' current Net Margin % is -1,473.33%.
How does Enzolytics' Net Margin % compare to competitors?
Enzolytics' Net Margin % of -1,473.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Enzolytics and its competitors. Enzolytics's current Net Margin % is -1,473.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Net Margin % of -1,473.33%. The current Net Margin % is -1,473.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Enzolytics (ENZC), the current Net Margin % is -1,473.33% as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.